Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03637543 · ClinicalTrials.gov registry record · Phase 2

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Beth Israel Deaconess Medical Center.

Active
Registry status
Phase 2
Development phase
31
Enrollment target
5
Study locations

NCT03637543 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 31 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03637543, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
31 participants
Enrollment target
5
Study locations

Study Summary

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Nivolumab

Study Locations (5)

Massachusetts

  • St. Elizabeth's Medical Center - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston
  • DFCI South Shore - South Weymouth

New Hampshire

  • DFCI Londonderry - Londonderry

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2018-10-18
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Beth Israel Deaconess Medical Center

488 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03637543

The ClinicalTrials.gov registry entry for NCT03637543 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.

NCT03637543 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT03637543 about?

NCT03637543 is a clinical study titled "Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer". This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

What is the current status of trial NCT03637543?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-10-18. Estimated completion is 2026-12-31.

What conditions does trial NCT03637543 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03637543?

The interventions under investigation include: Nivolumab (DRUG).

Who is sponsoring clinical trial NCT03637543?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03637543 being conducted?

This trial has 5 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.